Abstract
Dual blockade of both EGFR and VEGFR pathways in EGFR-mutant NSCLC has shown enhanced antitumor efficacy versus EGFR-TKIs alone. Apatinib is an orally effective VEGFR-2 tyrosine kinase inhibitor (TKI). Previous studies have shown that apatinib (a TKI against VEGFR-2) combined with EGFR-TKI might prevent progression of the disease. This study aims to evaluate the efficacy and safety of apatinib plus EGFR-TKIs compared with chemotherapy for EGFR-TKI resistant NSCLC patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
